Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Braud

Showing results (171-180 of 497) with videos related to

Pageof 50
Sort By:
Nature Communications|May 13, 2020
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancersMaira Di Tano, Franca Raucci, Claudio Vernieri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trialFrancesca Ligorio, Giovanni Fucà, Leonardo Provenzano, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
Tumori|May 14, 2016
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancerArpine Gevorgyan, Giacomo Bregni, Giulia Galli, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature reviewGiulia Galli, Giulia Corrao, Martina Imbimbo, et al.
Future Oncology (London, England)|July 11, 2015
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic reviewSara Pusceddu, Filippo De Braud, Fabrizio Festinese, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 12, 2015
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerMaria Di Bartolomeo, Filippo Pietrantonio, Alessandro Pellegrinelli, et al.
Cellular Oncology (Dordrecht, Netherlands)|March 31, 2022
BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancerFrancesca De Santis, Sandra L Romero-Cordoba, Lorenzo Castagnoli, et al.
Cancers|April 30, 2021
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-PertuzumabFrancesca Ligorio, Giovanni Fucà, Emma Zattarin, et al.
Pageof 50

Showing results (171-180 of 497) with videos related to

Sort By:
Pageof 50
Nature Communications|May 13, 2020
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancersMaira Di Tano, Franca Raucci, Claudio Vernieri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trialFrancesca Ligorio, Giovanni Fucà, Leonardo Provenzano, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
Tumori|May 14, 2016
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancerArpine Gevorgyan, Giacomo Bregni, Giulia Galli, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature reviewGiulia Galli, Giulia Corrao, Martina Imbimbo, et al.
Future Oncology (London, England)|July 11, 2015
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic reviewSara Pusceddu, Filippo De Braud, Fabrizio Festinese, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 12, 2015
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerMaria Di Bartolomeo, Filippo Pietrantonio, Alessandro Pellegrinelli, et al.
Cellular Oncology (Dordrecht, Netherlands)|March 31, 2022
BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancerFrancesca De Santis, Sandra L Romero-Cordoba, Lorenzo Castagnoli, et al.
Cancers|April 30, 2021
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-PertuzumabFrancesca Ligorio, Giovanni Fucà, Emma Zattarin, et al.
Pageof 50